TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06963398: A Phase 1 Study, Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of HS-10529 Monotherapy in KRAS G12D Patients With Advanced Solid Tumors

Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 520 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT06963398 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06963398 Rescue Dossier →